Broadwood Partners Comments on STAAR Surgical’s Late and Troubling Disclosure in Deeply Flawed Sale Process to Alcon

NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the recent Current Report on Form 8-K filed by STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) with the U.S. Securities and Exchange Commission (“SEC”) of a “supplement” to the Company’s definitive proxy statement, filed on September 16, 2025, in connection with the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE: ALC). Broadwood, which owns 27.5% of STAAR